Bevacizumab therapy may contribute to irradiation deferral in patients with breast cancer and with central nervous system metastases: Findings of a case series

Clinical Breast Cancer

Volumn 12, Issue 4, 2012, Pages 282-286

  Kountourakis, Panteleimon ^a,b   Dokou, Anna ^a   Kardara, Eugenia ^a   Kaltsas, Serafeim ^a   Doufexis, Demetrios ^a   Tzovaras, Alexandros ^a   Mourgela, Sofia ^a   Ardavanis, Alexandros ^a  

^a Aghios Savvas Anti cancer Hospital   (Greece)

^b Oncology Centre   (Cyprus)

Author keywords

Bevacizumab; Breast cancer; Central nervous system; Choroidal metastases; Treatment

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; ZOLEDRONIC ACID;

ADULT; AGED; ARTERY EMBOLISM; ARTERY THROMBOSIS; ARTICLE; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CEREBELLUM METASTASIS; CHEMOTHERAPY INDUCED ANEMIA; CHOROID METASTASIS; CLINICAL ARTICLE; DISEASE COURSE; DRUG RESPONSE; HUMAN; HYPERTENSION; INTRADUCTAL CARCINOMA; NEUROTOXICITY; NEUTROPENIA; PROTEINURIA; SURVIVAL TIME; TRIPLE NEGATIVE BREAST CANCER; VEIN EMBOLISM; VEIN THROMBOSIS;

EID: 84864762373     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2012.04.002     Document Type: Article

References (22)

1. A.M. Jubb, T.Q. Pham, A.M. Hanby Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha and carbonic anhydrase IX in human tumours J Clin Pathol 57 2004 504 512 (Pubitemid 38621796)
2. M. Toi, K. Inada, S. Hoshina Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer Clin Cancer Res 1 1995 961 964
3. G. Gasparini, M. Toi, M. Gion Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma J Natl Cancer Inst 89 1997 139 147 (Pubitemid 27034790)
4. K. Miller, M. Wang, J. Gralow Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2007 2666 2676
5. P. Kountourakis, D. Doufexis, S. Maliou Bevacizumab combined with two-weekly paclitaxel as first-line therapy for metastatic breast cancer Anticancer Res 30 2010 2969 2971
6. D.W. Miles, A. Chan, L.Y. Dirix Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer J Clin Oncol 28 2010 3239 3247
7. N.J. Robert, V. Diéras, J. Glaspy Ribbon-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer J Clin Oncol 29 2011 1252 1260
8. B.J. Giantonio, P.J. Catalano, N.J. Meropol Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology Group Study E3200 J Clin Oncol 25 2007 1539 1544 (Pubitemid 46733080)
9. A. Ardavanis, D. Doufexis, P. Kountourakis Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review study BMC Cancer 9 2009 338
10. A. Flowers, V.A. Levin Management of brain metastases from breast carcinoma Oncol Williston Park 7 1993 21 26 (Pubitemid 23135215)
11. K. Altundag, M.L. Bondy, N.Q. Mirza Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis Cancer 110 2007 2640 2647 (Pubitemid 350250332)
12. N.U. Lin, E.P. Winer Brain metastases: the HER2 paradigm Clin Cancer Res 13 2007 1648 1655 (Pubitemid 46952930)
13. J.C. Bendell, S.M. Domchek, H.J. Burstein Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma Cancer 97 2003 2972 2977 (Pubitemid 36676250)
14. M.S. Gordon, K. Margolin, M. Talpaz Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J Clin Oncol 19 2001 843 850 (Pubitemid 32119100)
15. M.H. Fenner, K. Possinger Chemotherapy for breast cancer brain metastases Onkologie 25 2002 474 479 (Pubitemid 36160188)
16. U.Y. Arslan, B. Oksuzoglu, S. Aksoy Breast cancer subtypes and outcomes of central nervous system metastases Breast 20 2011 562 567
17. A.F. Eichler, I. Kuter, P. Ryan Survival in patients with brain metastases from breast cancer: the importance of HER-2 status Cancer 112 2008 2359 2367
18. S.I. Labidi, T. Bachelot, I. Ray-Coquard Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series Clin Breast Cancer 9 2009 118 121
19. K.C. De Braganca, Y.Y. Janjigian, C.G. Azzoli Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer J Neuro Oncol 100 2010 443 447
20. L. Amselem, E. Cervera, M. Díaz-Llopis Intravitreal bevacizumab (Avastin) for choroidal metastasis secondary to breast carcinoma: short-term follow-up Eye (Lond) 21 2007 566 567 (Pubitemid 46564160)
21. T. Wiegel, K.M. Kreusel, N. Bornfeld Frequency of asymptomatic choroidal metastasis in patients with disseminated breast cancer: results of a prospective screening programme Br J Ophthalmol 82 1998 1159 1161 (Pubitemid 28474872)
22. B. Besse, S.F. Lasserre, P. Compton Bevacizumab safety in patients with central nervous system metastases Clin Cancer Res 16 2010 269 278